Replies to post #11552 on Intellect Neurosciences Inc. (fka ILNS)

[buckiii2]

Would this be covered by ILNS ' s patent?
The research group directed by Dr Sandra Villegas, from the Biosciences Unit of the Department of Biochemistry and Molecular Biology at the UAB, designed a recombinant antibody fragment (the single-chain variable fragment scFv-h3D6), a derivative of bapineuzumab, which only consists of the active part trapping the etiological agent of the disease: the domains of the antibody responsible for the binding of Aß oligomers. Scientists observed how this antibody fragment protected from cell death in human cell-cultures and described the molecular mechanism by which this antibody fragment removed the Aß oligomers that cause the disease.